Core Viewpoint - The study reveals a mechanism by which the STING-CD38 signaling axis in macrophages promotes the survival of regulatory T cells (Tregs) and accelerates the progression of non-small cell lung cancer (NSCLC) driven by KRAS mutations, providing insights into the limited efficacy of STING agonists in clinical settings [2][3][6]. Group 1 - The STING-CD38 signaling axis in macrophages depletes NAD+ in the tumor microenvironment, thereby promoting Treg survival and creating an immunosuppressive state that facilitates tumor progression [3][4]. - In a KRAS G12D-driven NSCLC mouse model, STING activation in macrophages was found to enhance Treg survival and accelerate NSCLC progression [4][6]. - Mechanistic studies indicate that STING-mediated NF-κB activation upregulates CD38 in Siglec-F low macrophages, leading to the hydrolysis of extracellular NAD+ in the tumor microenvironment [5][6]. Group 2 - Genetic knockout of STING or CD38, or treatment with CD38 inhibitors, restores NAD+ levels, induces Treg apoptosis via the ART2-P2RX7 signaling axis, and enhances anti-tumor CD8+ T cell responses [6][9]. - Importantly, CD38 inhibitors can increase the sensitivity of NSCLC mice to low-dose anti-CTLA4 therapy, suggesting a potential therapeutic strategy for overcoming resistance in immune checkpoint blockade (ICB) [6][9].

Core Viewpoint - The cGAS-STING pathway plays a crucial role in detecting tumor-derived DNA, influencing both spontaneous and treatment-induced responses, and establishing a delicate balance between pathological inflammation and protective immune responses [2][3]. Group 1: Overview of cGAS-STING Pathway - The review published in Nature Reviews Cancer discusses the dual roles of the cGAS-STING pathway in cancer, highlighting both its pro-cancer and anti-cancer effects [5]. - It provides a comprehensive analysis of the diverse sources of cGAS-STING activating ligands and their prevalence in various human cancers, including DNA abnormalities caused by chromosomal instability, replication stress, telomere shortening, and treatment-induced DNA damage [7][8]. Group 2: Dual Role in Tumor Progression - The review emphasizes the different outcomes mediated by cGAS-STING activation at various stages of tumor initiation, progression, and metastasis, noting its critical anti-tumor role during tumor initiation and potential pro-tumor effects during tumor progression [8][12]. Group 3: Clinical Implications and Challenges - The review systematically reviews clinical trial results of STING agonists, such as ADU-S100 and MK-1454, and analyzes the limited efficacy due to factors like short drug half-life and differences in tumor microenvironments between humans and mice [14]. - It details the multi-layered negative regulatory networks that limit the anti-tumor effects of the cGAS-STING pathway, including DNA uptake barriers and differential responses of innate and adaptive immune cells [14]. Group 4: Future Directions - The review proposes several optimization strategies for enhancing the efficacy of cGAS-STING-targeted therapies, such as selective induction of mitochondrial DNA release and the development of drug delivery systems that enable spatiotemporal control of activation [15]. - It also suggests that transient inhibition of cGAS-STING signaling may normalize immune responses and enhance the effectiveness of immunotherapy, referencing recent successful cases in early clinical trials [16][17].

Core Viewpoint - Colorectal cancer (CRC) is the third leading cause of cancer-related deaths globally, with over 30% of patients diagnosed at an advanced stage. Neoadjuvant radiotherapy plays a crucial role in both curative and palliative treatments, yet only 15%-30% of rectal cancer patients achieve pathological complete response (pCR), highlighting the need to understand mechanisms behind radiotherapy failure [2][5]. Group 1 - A new study published in Cell Reports Medicine identifies a subtype of cancer-associated fibroblasts (CAFs) called ilCAF, which responds positively to radiotherapy. Activation of the IFN-γ/STING signaling pathway in ilCAF enhances the effectiveness of radiotherapy and overcomes resistance [3][6]. - The study utilized single-cell RNA sequencing to discover ilCAF characterized by high expression of interferon regulatory factor-1 (IRF1), which is enriched in tumors that respond well to radiotherapy [6][9]. - The activation of the IFN-γ/STING signaling pathway reprograms the tumor microenvironment, enhancing anti-tumor immunity by attracting T cells and dendritic cells through the secretion of chemokines CCL4 and CCL5 [6][12]. Group 2 - The increase in ilCAF numbers enhances endogenous immune responses, contributing to improved overall survival rates in rectal cancer patients. The combination of STING agonists with radiotherapy shows significant translational potential for cancer treatment [9][12]. - Early initiation of the combined strategy of STING agonists and radiotherapy may enhance initial anti-tumor responses and mitigate the emergence of treatment resistance [9].